Scott H. Okuno

12.4k total citations · 1 hit paper
178 papers, 5.8k citations indexed

About

Scott H. Okuno is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Scott H. Okuno has authored 178 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 122 papers in Pulmonary and Respiratory Medicine, 88 papers in Oncology and 38 papers in Surgery. Recurrent topics in Scott H. Okuno's work include Sarcoma Diagnosis and Treatment (95 papers), Vascular Tumors and Angiosarcomas (28 papers) and Cardiac tumors and thrombi (27 papers). Scott H. Okuno is often cited by papers focused on Sarcoma Diagnosis and Treatment (95 papers), Vascular Tumors and Angiosarcomas (28 papers) and Cardiac tumors and thrombi (27 papers). Scott H. Okuno collaborates with scholars based in United States, Canada and United Kingdom. Scott H. Okuno's co-authors include Margaret von Mehren, Robert S. Benjamin, Robert G. Maki, Denise K. Reinke, John H. Edmonson, Scott M. Schuetze, Mark Agulnik, Dennis A. Priebat, Jeff A. Sloan and Shreyaskumar Patel and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Scott H. Okuno

172 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002

2007 531 citations Robert G. Maki, J. Kyle Wathen et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Scott H. Okuno

Since Specialization

Citations

This map shows the geographic impact of Scott H. Okuno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott H. Okuno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott H. Okuno more than expected).

Fields of papers citing papers by Scott H. Okuno

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott H. Okuno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott H. Okuno. The network helps show where Scott H. Okuno may publish in the future.

Co-authorship network of co-authors of Scott H. Okuno

This figure shows the co-authorship network connecting the top 25 collaborators of Scott H. Okuno. A scholar is included among the top collaborators of Scott H. Okuno based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott H. Okuno. Scott H. Okuno is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Phase II Multicenter Trial of Trabectedin in Combination with Olaparib in Patients with Advanced Unresectable or Metastatic Sarcoma 2025 ·Clinical Cancer Research ·Brittany L. Siontis, John D. Rice, Scott M. Schuetze, (unknown), Christina V. Angeles, (unknown), (unknown), Salim S. Hayek, Steven I. Robinson, Scott H. Okuno, (unknown), Rashmi Chugh	0
2	Tolerability and Outcomes for Treatment of Older Myxoid Liposarcoma Population 2024 ·Cancers ·(unknown), (unknown), Brittany L. Siontis, Steven I. Robinson, Scott H. Okuno, Matthew T. Houdek, Meng Xu‐Welliver, (unknown)	0
3	Unplanned Excision of Synovial Sarcoma: Factors Associated with Recurrence and Survival 2024 ·Cancers ·(unknown), (unknown), (unknown), Steven I. Robinson, Scott H. Okuno, Brittany L. Siontis, (unknown), Peter S. Rose, Meng Xu‐Welliver, Matthew T. Houdek	1
4	Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast 2023 ·Clinical Cancer Research ·Amy C. Degnim, Brittany L. Siontis, Safia K. Ahmed, Tanya L. Hoskin, Tina J. Hieken, James W. Jakub, Christian L. Baum, Courtney N. Day, (unknown), (unknown), Jodi M. Carter, (unknown), Katrina N. Glazebrook, Aparna Vijayasekaran, Scott H. Okuno, Ivy A. Petersen	2
5	Neoadjuvant pazopanib in nonrhabdomyosarcoma soft tissue sarcomas (ARST1321): A report of major wound complications from the Children's Oncology Group and NRG Oncology 2023 ·Journal of Surgical Oncology ·Mark L. Kayton, Aaron R. Weiss, Wei Xue, Odion Binitie, (unknown), R. Lor Randall, Joel Sorger, Douglas S. Hawkins, Sheri L. Spunt, Dian Wang, Lynn Million, Stephanie Terezakis, Edwin Choy, Scott H. Okuno, Rajkumar Venkatramani, Yen‐Lin Chen, Thomas J. Scharschmidt	4
6	Patient Understanding of Chemotherapy and Goals of Care as Provided by Different Care Team Members 2023 ·Journal of Cancer Education ·(unknown), S. Basu, (unknown), (unknown), (unknown), (unknown), Scott H. Okuno	1
7	Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma 2019 ·Journal of Clinical Oncology ·Lara E. Davis, Vanessa Bolejack, Christopher W. Ryan, Kristen N. Ganjoo, Elizabeth T. Loggers, Sant P. Chawla, Mark Agulnik, Michael B. Livingston, Damon R. Reed, (unknown), Daniel A. Rushing, Scott H. Okuno, Denise K. Reinke, Richard F. Riedel, Steven Attia, Leo Mascarenhas, Robert G. Maki	174
8	Evaluating the Role of Adjuvant Radiotherapy in the Management of Sacral and Vertebral Chordoma: Results from a National Database 2019 ·World Neurosurgery ·Yagiz U. Yolcu, Waseem Wahood, Mohammed Ali Alvi, Panagiotis Kerezoudis, Scott H. Okuno, Robert L. Foote, Mohamad Bydon	17
9	Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma 2014 ·Journal of Clinical Oncology ·Sant P. Chawla, Lee D. Cranmer, Brian A. Van Tine, Damon R. Reed, Scott H. Okuno, James E. Butrynski, Douglas R. Adkins, Andrew Hendifar, Stew Kroll, Kristen N. Ganjoo	122
10	Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors 2012 ·Annals of Oncology ·Mark A. Dickson, Scott H. Okuno, Mary Louise Keohan, Robert G. Maki, David R. D’Adamo, Timothy Akhurst, Cristina R. Antonescu, Gary K. Schwartz	88
11	RTOG Phase II Trial of Preoperative Image Guided Radiotherapy (IG-RT) For Primary Soft Tissue Sarcoma of the Extremity: Acute Toxicity Report 2011 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), (unknown), David G. Kirsch, Scott H. Okuno, John M. Kane, Xiaoming Li, David Roberge, (unknown), Thomas F. DeLaney, Burton Eisenberg	8
12	Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002 breakdown → 2007 ·Journal of Clinical Oncology ·Robert G. Maki, J. Kyle Wathen, Shreyaskumar Patel, Dennis A. Priebat, Scott H. Okuno, Brian L. Samuels, Michael Fanucchi, David C. Harmon, Scott M. Schuetze, Denise K. Reinke, Peter F. Thall, Robert S. Benjamin, Laurence H. Baker, Martee L. Hensley	531
13	Safety, tolerability and preliminary efficacy of the anti-IGF-IR monoclonal antibody CP-751,871 in patients with sarcomas and adrenocortical tumors. 2007 ·Molecular Cancer Therapeutics ·David Olmos, R. Molife, Scott H. Okuno, Frank Worden, Gary D. Hammer, Timothy A. Yap, Heather Shaw, Scott M. Schuetze, (unknown), Antonio Gualberto, Johann S. de Bono, Paul Haluska	7
14	Surgically Managed Gastrointestinal Stromal Tumors: A Comparative and Prognostic Analysis 2007 ·Annals of Surgical Oncology ·Imran Hassan, (unknown), Roman Shyyan, Eric J. Dozois, Thomas C. Smyrk, Scott H. Okuno, Cathy D. Schleck, David O. Hodge, John H. Donohue	100
15	Organ preservation for advanced laryngeal carcinoma 2006 ·Head & Neck ·Robert L. Foote, (unknown), (unknown), (unknown), Paul D. Brown, Yolanda I. Garces, Scott H. Okuno, Scott E. Strome	11
16	Causes and Outcomes of Spontaneous Pneumothoraces in Solid Tumor Cancer Patients: An Update for the Medical Oncologist 2006 ·Journal of Thoracic Oncology ·(unknown), Scott H. Okuno, Aminah Jatoi	6
17	2003 ·American Journal of Clinical Oncology ·Randolph S. Marks, David L. Graham, Jeff A. Sloan, Shauna Hillman, (unknown), James E. Krook, Scott H. Okuno, James A. Mailliard, Tom R. Fitch, (unknown)	6
18	A Phase II Study of the Dolastatin 15 Analogue LU 103793 in the Treatment of Advanced Non–Small-Cell Lung Cancer 2003 ·American Journal of Clinical Oncology ·Randolph S. Marks, David L. Graham, Jeff A. Sloan, Shauna Hillman, (unknown), James E. Krook, Scott H. Okuno, James A. Mailliard, Tom R. Fitch, (unknown)	31
19	Combination chemotherapy for desmoid tumors 2003 ·Cancer ·Scott H. Okuno, John H. Edmonson	91
20	Phase III Controlled Evaluation of Glutamine for Decreasing Stomatitis in Patients Receiving Fluorouracil (5-FU)-Based Chemotherapy 1999 ·American Journal of Clinical Oncology ·Scott H. Okuno, (unknown), Charles L. Loprinzi, Jeff A. Sloan, Beth LaVasseur, (unknown), (unknown), (unknown), Larry P. Ebbert, (unknown), John C. Michalak, (unknown)	68

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact